Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
Eligibility Criteria
- * Male and female participants ≥ 18 to ≤ 55 years (inclusive) at the time of signing the informed consent.
- * Body mass index between 18 and 30 kg/m\^2, inclusive, at screening.
- * Men (even with a history of vasectomy) with partners of childbearing potential must agree to practice sexual abstinence or use a male barrier method of contraception (ie, male condom with spermicide) in addition to a second method of acceptable contraception by female partner from Check-in until 30 days after the last dose of investigational product.
- * Participant must be overtly healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) recording(s) at the screening and Day 1 visits.
- * History of malignancy of any type.
- * History of esophageal, gastric, or duodenal ulceration prior to screening visit.
- * Evidence of active bacterial, viral, fungal or parasitic infections within the last 30 days prior to study day 1.
- * History or evidence of clinically significant arrhythmia at screening, or Day 1 ECG.
- * A QT interval corrected for heart rate (HR) based on the Fridericia method (QTcF) interval \> 450 ms in all participants regardless of biological sex or history/evidence of long QT syndrome at screening or study day 1.
- * Positive results for human immunodeficiency virus (HIV) antibodies, HIV antigen, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus ribonucleic acid (RNA) at screening.
- * History of active tuberculosis (TB) infection, current symptoms concerning for active TB, or positive or indeterminate interferon gamma release assay (IGRA).
- * Positive test for drugs, cotinine (tobacco use) or alcohol use at screening or on Day 1.
- * Female participants of childbearing potential unwilling to use 2 protocol specified highly effective methods of contraception during treatment and for an additional 30 days after the last dose of investigational product.
- * Alcohol consumption from 48 hours prior to study day 1.
- * Use of tobacco- or nicotine-containing products within 6 months prior to study day 1.
Ages Eligible for Study
18 Years to 55 Years
Sexes Eligible for Study
ALL
Accepts Healthy Volunteers
Yes